Profile of levodopa-induced dyskinesia in patients of Parkinson’s disease: a record based study

References

• Dewey RB Jr. Management of motor complications in Parkinson’s disease. Neurology. 2004;62(6 Suppl 4):S3–7.
   PubMed Web of Science ®Google Scholar
• Müller T, Russ H. Levodopa, motor fluctuations and dyskinesia in Parkinson’s disease. Expert Opin Pharmacother. 2006;7:1715–30.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Obeso JA. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson’s disease: implications for the early use of COMT inhibitors. Neurology. 2000;55(11 Suppl 4):S72–7.
   PubMed Web of Science ®Google Scholar
• Jenner P. Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. J Neurol. 2000;247(Suppl 2):II43–50.
   PubMedGoogle Scholar
• Mabrouk OS, Mela F, Calcagno M, Budri M, Viaro R, Dekundy A, et al. GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats. ACS Chem Neurosci. 2013;4:808–16.
   PubMed Web of Science ®Google Scholar
• Fox SH. Non-dopaminergic treatments for motor control in Parkinson's disease. Drugs. 2013;73:1405–15.
   PubMed Web of Science ®Google Scholar
• Péchevis M, Clarke CE, Vieregge P, Khoshnood B, Deschaseaux-Voinet C, Berdeaux G, et al. Effects of dyskinesias in Parkinson’s disease on quality of life and health related costs: a prospective European study. Eur J Neurol. 2005;12:956–63.
   PubMed Web of Science ®Google Scholar
• Müller B, Assmus J, Herlofson K, Larsen JP, Tysnes OB. Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson's disease. Parkinsonism Relat Disord. 2013;19(11):1027–32.
   PubMed Web of Science ®Google Scholar
• Goetz CG. Rating scales for dyskinesias in Parkinson's disease. Mov Disord. 1999;14(Suppl 1):48–53.
   PubMedGoogle Scholar
• Unified Parkinson's Disease Rating Scale. Available from: http://www.mdvu.org/library/ratingscales/pd/updrs.pdf (accessed 2013 August 14).
   Google Scholar
• Das SK, Misra AK, Ray BK, Hazra A, Ghosal MK, Chaudhuri A, et al. Epidemiology of Parkinson disease in the city of Kolkata, India: a community-based study. Neurology. 2010;75(15):1362–9.
   PubMed Web of Science ®Google Scholar
• Gourie-Devi M, Gururaj G, Satishchandra P, Subbakrishna DK. Prevalence of neurological disorders in Bangalore, India: a community-based study with a comparison between urban and rural areas. Neuroepidemiology. 2004;23:261–8.
   PubMed Web of Science ®Google Scholar
• Alladi PA, Mahadevan A, Yasha TC, Raju TR, Shankar SK, Muthane U. Absence of age-related changes in nigral dopaminergic neurons of Asian Indians: relevance to lower incidence of Parkinson's disease. Neuroscience. 2009;159:236–45.
   PubMed Web of Science ®Google Scholar
• Grandas F, Galiano ML, Tabernero C. Risk factors for levodopa-induced dyskinesias in Parkinson’s disease. J Neurol. 1999;246:1127–33.
   PubMed Web of Science ®Google Scholar
• Kostić VS, Marinković J, Svetel M, Stefanova E, Przedborski S. The effect of stage of Parkinson’s disease at the onset of Levodopa therapy on development of motor complications. Eur J Neurol. 2002;9(1):9–14.
   PubMed Web of Science ®Google Scholar
• Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M. Reduction in dyskinesia evaluation in Parkinson's disease (STRIDE-PD) investigators. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord. 2013;28(8):1064–71.
   PubMed Web of Science ®Google Scholar
• Kum WF, Gao J, Durairajan SS, Man SC, Xie LX, Lu JH, et al. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease. J Clin Neurosci. 2009;16:1034–7.
   PubMed Web of Science ®Google Scholar
• Sartorius N. The ICD-10 classification of mental and behavioural disorders clinical descriptions and diagnostic guidelines. Available from: www.who.int/classifications/icd/en/GRNBOOK.pdf (accessed 2013 August 14).
   Google Scholar
• UK Parkinson’s Disease Society Brain Bank Clinical Diagnostic Criteria. Available from: http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetPdf.cgi?id = phd000042 (accessed 2013 August 14).
   Google Scholar
• Haddad PM, Das A, Keyhani S, Chaudhry IB. Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons. J Psychopharmacol. 2012;26:15–26.
   PubMed Web of Science ®Google Scholar
• Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol. 2011;26(Suppl 1): 1–58.
   PubMed Web of Science ®Google Scholar
• Sharma JC, Macnamara L, Hasoon M, Vassallo M, Ross I. Cascade of Levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade). Parkinsonism Relat Disord. 2006;12:499–505.
   PubMed Web of Science ®Google Scholar
• Sharma JC, Ross IN, Rascol O, Brooks D. Relationship between weight, Levodopa and dyskinesia: the significance of Levodopa dose per kilogram body weight. Eur J Neurol. 2008;15:493–6.
   PubMed Web of Science ®Google Scholar
• Currie LJ, Harrison MB, Trugman JM, Bennett JP Jr, Wooten GF. Early morning dystonia in Parkinson's disease. Neurology. 1998;51:283–5.
   PubMed Web of Science ®Google Scholar
• Cubo E, Gracies JM, Benabou R, Olanow CW, Raman R, Leurgans S, et al. Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch Neurol. 2001;58:1379–82.
   PubMed Web of Science ®Google Scholar
• Jenner P. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology. 2004;62(1 Suppl 1):S47–55.
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Pramipexole versus Levodopa as initial treatment for Parkinson’s disease: a randomized controlled trial. Parkinson Study Group. JAMA. 2000;284(15):1931–8.
   PubMed Web of Science ®Google Scholar
• Rascol O, Fabre N. Dyskinesia: levodopa-induced and tardive dyskinesia. Clin. Neuropharmacol. 2001;24:313–23.
   Web of Science ®Google Scholar